Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 8/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532007 | 0.89 | ADORA1 (0.39) | ADORA1ADORA3ADORA2APARP1 | |
| SCHEMBL5517383 | 0.88 | ADORA1 (0.39) | ADORA1ADORA3ADORA2APARP1HTR2C | |
| SCHEMBL5522404 | 0.86 | PARP1 (0.46) | ADORA1ADORA3ADORA2APARP1 | |
| SCHEMBL5522593 | 0.85 | PARP1 (0.38) | ADORA1ADORA3ADORA2APARP1 | |
| SCHEMBL5534187 | 0.85 | PARP1 (0.38) | ADORA1ADORA3ADORA2APARP1 | |
| SCHEMBL5526082 | 0.85 | PARP1 (0.45) | ADORA1ADORA3ADORA2APARP1 | |
| SCHEMBL5528810 | 0.85 | HTR2C (0.43) | ADORA1ADORA3ADORA2APARP1HTR2C | |
| SCHEMBL5521518 | 0.85 | PARP1 (0.47) | ADORA1ADORA3ADORA2APARP1 | |
| SCHEMBL5529526 | 0.85 | PARP1 (0.48) | ADORA1ADORA3ADORA2APARP1 | |
| SCHEMBL5530509 | 0.84 | PARP1 (0.48) | ADORA1ADORA3ADORA2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2468748-B1 | Pyrazoloquinolones are potent parp inhibitors | ABBVIE INC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8546368-B2 | Pyrazoloquinolones are potent PARP inhibitors | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2468748-A1 | Pyrazoloquinolones are potent parp inhibitors | Abbott Laboratories (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | ADORA1 3756/4885ADORA3 3786/4885ADORA2A 3265/4885 |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | ADORA1 3756/4885ADORA3 3786/4885ADORA2A 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.